Product Details: Stugeron Forte (Cinnarizine)

Brand Name Options - Manufacturer: Janssen-Cilag

Description

Stugeron Forte tablets contain the active ingredient cinnarizine, which is a type of medicine called an antihistamine. It is used for the control of vestibular symptoms of both peripheral and central origin and for the control of labyrinthine disorders including vertigo, dizziness, tinnitus, nystagmus, nausea and vomiting. It is also an adjunct therapy for symptoms of peripheral arterial disease.

Directions

Adults and children over the age of 12 years:
Peripheral circulatory disorders: 2 to 3 tablets of 75 mg daily.
Disorders of balance: 1 tablet of 75 mg daily.
The maximum recommended dosage should not exceed 225 mg (3 tablets) daily - if necessary the dosage may be divided over 2 or 3 intakes per day. As the effect of cinnarizine on vertigo is dose dependant, the dosage should be increased progressively.

Side Effects

The most common antihistaminic side-effect of cinnarizine is sedation which can vary from slight drowsiness to deep sleep, and including inability to concentrate, lassitude, dizziness, and inco-ordination. Sedative effects, when they occur, may diminish after a few days.
Other side-effects include gastro-intestinal disturbances such as nausea, vomiting, diarrhoea or constipation, anorexia or increased appetite and epigastric pain.
Somnolence and gastro-intestinal disturbances are usually transient and may often be prevented by achieving the optimum dosage gradually.
Cinnarizine may also produce antimuscarinic effects such as blurred vision, difficulty in micturition, dysuria, dryness of mouth and tightness of chest.
Central effects may include muscular weakness, headache and euphoria.
Weight gain, perspiration or allergic reactions may be observed. Cases of lichen planus and lupus-like symptoms and an isolated case of cholestatic jaundice have been reported.
In elderly people cases of aggravation or an appearance of extrapyramidal symptoms sometimes associated with depressive feelings have been described during prolonged therapy. The treatment should be discontinued in such cases.
Interactions:
Cinnarizine may enhance the sedative effect of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, tricyclic antidepressants, sedatives and tranquillisers.
The side-effects of anticholinergic substances such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of antihistamines.
Monoamine-oxidase inhibitors may enhance the antimuscarinic effects of antihistamines.
Diagnostic interference:
Because of its antihistamine effect, cinnarizine may prevent otherwise positive reactions to dermal reactivity indicators if used up to 4 days prior to skin testing.

Active Ingredients

Cinnarizine